key: cord-0873213-rpfj5ac2
authors: Lin, Timothy P.H.; Ko, Chung-Nga; Zheng, Ke; Lai, Kenny H.W.; Wong, Raymond L.M.; Lee, Allie; Zhang, Shaochong; Huang, Suber S.; Wan, Kelvin H.; Lam, Dennis S.C.
title: COVID-19: Update on Its Ocular Involvements, and Complications From Its Treatments and Vaccinations
date: 2021-11-24
journal: Asia Pac J Ophthalmol (Phila)
DOI: 10.1097/apo.0000000000000453
sha: 3e1303f0d6e9924acfb0543449510210d52ce68b
doc_id: 873213
cord_uid: rpfj5ac2

The coronavirus disease 2019 (COVID-19) came under the attention of the international medical community when China first notified the World Health Organization of a pneumonia outbreak of then-unknown etiology in Wuhan in December 2019. Since then, COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has appalled the world by spreading at a pandemic speed. Although ophthalmologists do not directly engage in the clinical care of COVID-19 patients, the ophthalmology community has become aware of the close ties between its practice and the pandemic. Not only are ophthalmologists at heightened risk of SARS-CoV-2 exposure due to their physical proximity with patients in routine ophthalmic examinations, but SARS-CoV-2 possesses ocular tropism resulting in ocular complications beyond the respiratory tract after viral exposure. Furthermore, patients could potentially suffer from adverse ocular effects in the therapeutic process. This review summarized the latest literature to cover the ophthalmic manifestations, effects of treatments, and vaccinations on the eye to aid the frontline clinicians in providing effective ophthalmic care to COVID-19 patients as the pandemic continues to evolve.

of the worst pandemics the world has witnessed, continues to evolve since its advent in December 2019 with the emergence of novel variants. 1 As of September 2021, the case count of the COVID-19 pandemic has surpassed 200 million, with a death toll of 5 million. Ophthalmology, like all other medical specialties, has been substantially impacted by the pandemic in its practice. 2, 3 As the pandemic unfolded, the literature has consistently reported the tropism of the SAR-CoV-2 for the ocular surface and retina due to the extrapulmonary expression of ACE2 and TMPRSS2 receptors. 4, 5 This tropism renders the eye a potential portal of entry for SARS-CoV-2. 6 Early in the course of the outbreak, it was reported that conjunctivitis could be the first and only clinical manifestation among COVID-19 patients. 4, 7, 8 The SARS-CoV-2 has also been isolated from ocular surface specimens such as tears and conjunctival swabs from patients with COVID-19. 9,10 As these initial observations raised cautions against the ocular involvement of COVID-19, there was a surge in reports of ophthalmic manifestations at additional anatomical locations of the eye beyond just the ocular surface directly exposed to the coronavirus in the environment. 11, 12 Given the devastating effect of the COVID-19 pandemic on public health and its disastrous socioeconomic impact, there has been a relentless search for effective treatment strategies and vaccines to contain the pandemic. Chloroquine (CQ) and hydroxychloroquine (HCQ), which are known to result in retinal toxicity, have initially been proposed as a treatment of COVID-19. 13 Steroids used in COVID-19 were also associated with different ocular side effects such as ocular hypertension and endogenous endophthalmitis. 14 With the emergency use authorization of novel vaccines, adverse ocular outcomes have also been reported in the latest literature. Although ophthalmologists are rarely directly engaged in the clinical management of COVID-19 patients, it remains crucial to promptly recognize the ocular findings in these contexts. This review summarized results and data from the latest literature regarding the ophthalmic manifestations of COVID-19 and the adverse ocular outcomes secondary to treatment and vaccination to update ophthalmologists in the face of such patients.

A systematic search of the literature on PubMed for articles about ophthalmic manifestations of COVID-19, adverse ocular effects from COVID-19 treatment, and vaccination were conducted. The following key words were used for searching the database: ("coronavirus" OR "covid-19" OR "sars-cov-2") AND ("eye" OR "ocular" OR "ophthalmic" OR "ophthalmology" OR "eyelid" OR "conjunctiva" OR "cornea" OR "uvea" OR "lens" OR "retina" OR "orbit" OR "ophthalmoplegia"). The final search was performed on September 10, 2021. Only articles in English were included. The references of the retrieved full texts were also reviewed and the relevant articles were included.

A total of 3767 studies were initially identified after searching according to the search strategy above. After title and abstract screening, 295 studies were chosen for full-text evaluation. Finally, 88 studies were included in this study. The ophthalmic manifestations of COVID-19 in different parts of the eye, and the adverse ocular effects resulting from COVID-19 treatment and vaccination were discussed in the following sections. The ocular findings, management, and outcomes in these cases were summarized in Tables 1 and 2 .

The ocular surface was postulated to be a portal of entry and potential route of transmission of SARS-CoV-2 early in the course of the pandemic. Notably, the expression of ACE2 and TMPRSS2 was observed in conjunctival and cornea tissues. 4 ACE2 serves as the key cell-surface receptor which binds the viral spike protein of SARS-CoV-2, 15 and the subsequent viral entry involves TMPRSS2, a cell surface-associated protease. 16 In view of the ocular surface susceptibility to the virus, it was hypothesized that primary viral infection of the ocular surface could induce local immune or inflammatory responses and resulting in the reported spectrum manifestations such as conjunctival hyperemia, tearing, and chemosis. 17 Coronavirus is known to cause conjunctivitis in humans, 18 and conjunctivitis was the most commonly reported ophthalmic manifestation of COVID-19. 19 The prevalence of conjunctivitis varied from <1% to 63.6%. 20, 21 Although conjunctivitis were the initial presenting symptoms of mild COVID-19 cases which were otherwise asymptomatic, 22 it was also reported as a late manifestation and on the more severe spectrum of the disease. 23, 24 A meta-analysis concluded that the overall rate of conjunctivitis in COVID-19 was 1.1%, and it was 3% and 0.7% in severe and nonsevere COVID-19 patients, respectively. 25 The common symptoms of conjunctivitis associated with COVID-19 infection included conjunctival hyperemia, foreign body sensation, hypersecretion, chemosis, and epiphora. 17 The differential diagnosis of conjunctivitis associated with COVID-19 includes all causes of red eye before the COVID-19 era. In the current context, it may also reflect either the direct viral or immune response to SARS-CoV-2, or ocular surface disturbances in the setting of COVID-19 patients admitted to the intensive care unit (ICU). 26 As many cases of conjunctivitis in COVID-19 were the initial or sole clinical feature of the infection, it presents a diagnostic challenge for frontline clinicians to ascertain a diagnosis of COVID-19-associated conjunctivitis. Although it is possible to perform real-time polymerase chain reaction (RT-PCR) of tears and conjunctival secretions, the detection rate of SARS-CoV-2 from ocular surface specimens was low. Wu et al reported that the detection rate of conjunctival SARS-CoV-2 was only 16.7%, as compared with 91.7% from nasopharyngeal swabs in COVID-19 patients with ocular abnormalities. 17 Similar findings were confirmed by Zhou et al. 27 The low yield of SARS-CoV-2 detection in ocular surface specimens could be attributed to the inclusion of patients with asymptomatic or mild diseases. 27 Alternatively, in a recent study that included only patients with moderate to severe COVID-19 without ocular involvement, it has reported a SARS-CoV-2 detection rate of up to 24%. 28 This implied the presence of SARS-CoV-2 in the ocular surface was likely related to the disease severity, and the absence of ocular manifestations does not safely exclude the possibility of viral shedding from tears. Therefore, clinicians ought to maintain a high index of suspicion for patients presenting with conjunctivitis or signs of ocular surface inflammation and exercise contact precaution during ocular examination in the COVID-19 era. 29 Almost all cases of conjunctivitis related to COVID-19 were selflimiting in nature, which resolved with conservative management without subsequent ocular or systemic sequelae. 30 Besides conjunctivitis, ocular surface manifestations of COVID-19 reported in the literature also include keratoconjunctivitis [31] [32] [33] and episcleritis. 34, 35 It is notable that as SARS-CoV-2 infection of the ocular surface induces immune and inflammatory dysregulations and can potentially compromise the ocular immune privilege, 36 cases of acute corneal graft rejection in patients with COVID-19 have also been reported in the literature. 37

Although orbital involvement in COVID-19 infection remained uncommon, cases of orbital cellulitis as the presenting clinical feature of COVID-19 in pediatric patients have been reported. 38 More severe orbital complications could occur in COVID-19 patients with coexisting systemic comorbidities and the use of immunosuppressive agents such as steroids. Various cases of development of rhino-orbital mucormycosis were reported in COVID-19 patients with preexisting diabetes mellitus (DM) and subjected to parenteral broadspectrum antibiotics and steroids. [39] [40] [41] [42] [43] [44] [45] [46] In these patients, ophthalmic examination revealed extensive edema of the periorbital region with soft tissue necrosis along the eyelids, proptosis, conjunctival edema, exposure keratopathy, decreased visual acuity, and restricted extraocular movement. 47 Fatal cases resulting from rhino-orbital cerebral mucormycosis in COVID-19 have also been documented. 48 Of note, there was a case series of 13 previously immunocompetent and nondiabetic patients developing new-onset DM complicated by rhino-orbial mucormycosis following COVID-19 infection, in which aggressive surgical intervention including orbital exenteration was necessary. 49 Among these 13 cases, 6 received no steroids or immunomodulators. 49 Therefore, ophthalmologists and clinicians involved in the care of COVID-19 patients ought to be aware of the possibility of recent-onset diabetes and its potentially devastating orbital consequences.

As the ACE2 receptors which bind the SARS-CoV-2 viral spike proteins are also found in other anatomical locations of the eye besides the ocular surface, it is also possible for the virus to produce ophthalmic manifestations at these sites. Following an initial episode of conjunctivitis, panuveitis with the presence of decreased visual acuity, anterior chamber cells, posterior synechiae, vitritis, optic nerve swelling with peripapillary subretinal fluid and choroidal folds was reported as a presenting clinical feature in a patient who was subsequently diagnosed with COVID-19. 50 Retina OCT changes of the retina were also reported in COVID-19 with hyper-reflective lesions at the level of retinal ganglion cells and inner plexiform layers. 51 Fundus examination revealed cotton wool spots and microhemorrhages along the retinal arcade suggestive of ischaemic changes, flame-shaped hemorrhage, and macular hemorrhage with hard exudates. [51] [52] [53] Despite the presence of retinal manifestations, these patients have no visual symptoms. There was also a report of sight-threatening atypical acute retinal necrosis due to Varicella-Zoster Virus occurring Neuro-ophthalmology Neuro-ophthalmic manifestations of COVID-19 have also been reported in the literature. 55 COVID-19 could result in ophthalmoplegia, diplopia, cranial nerve palsies, acute vision loss, and defective pupillary responses as described in the cases below.

Miller Fisher syndrome (MFS), characterized by a triad of ophthalmoplegia, ataxia, and areflexia, may also be associated with COVID-19 infection. MFS is a variant of Guillain-Barre syndrome, defined as an acute peripheral neuropathy after exposure to various viral, bacterial, or fungal pathogens. Classical development of MFS with bilateral ophthalmoplegia, ataxia, and hyporeflexia subsequently improved upon treatment with intravenous immunoglobulin have been reported in COVID-19 patients. 56, 57 Diplopia and ophthalmoplegia due to cranial nerve palsies in COVID-19 patients have also been reported. Dinkin et al 58 reported a case of unilateral oculomotor nerve palsy with magnetic resonance imaging (MRI) demonstrating T2 hyperintensity and enlargement of the left oculomotor nerve following COVID-19 development. Falcone et al reported a case of unilateral abducens nerve palsy with MRI findings of lateral rectus muscle atrophy in a middle-aged patient 5 weeks after COVID-19 development. 59 Similar findings of ophthalmoplegia due to cranial nerve palsies were reported in later studies, 60-63 and complete recovery was possible upon treatment and recovery from COVID-19. 61 Alternatively, COVID-19 infection could also result in diplopia due to the development of postinfectious myasthenia gravis. In such case, acetylcholine receptor antibodies were detected serologically alongside antibodies against SARS-CoV-2 one month following COVID-19; the patient showed improvement with the administration of intravenous immunoglobulin and pyridostigmine. 64 Bilateral subacute vision loss secondary to neuromyelitis optica were present in a young patient simultaneously positive for SARS-CoV-2 and myelin oligodendrocyte glycoprotein (MOG) IgG antibodies. 65 The patient's visual acuity improved rapidly after administration of intravenous methylprednisolone followed by oral prednisolone taper.

Infection of SARS-CoV-2 was also associated with systemic inflammatory response and coagulation activation. The binding of SARS-CoV-2 to ACE2 receptors within vascular endothelial cells was hypothesized to result in systemic endothelial dysfunction and a state of hypercoagulability. The state of hypercoagulability has important implications to the eye as occlusion of retinal blood vessels by thromboembolism could result in serious ophthalmic complications. 66 Acute vision loss in COVID-19 patients attributed to vascular complications of COVID-19 has been reported in the literature. These could manifest as an ophthalmic artery or central retinal artery/vein occlusion and ischemic optic neuropathy. [67] [68] [69] [70] [71] [72] [73] [74] [75] Furthermore, hypercoagulability can also result in vascular occlusion beyond the retina at the central nervous system and manifest as bilateral acute vision loss due to infarct of the visual cortices in bilateral occipital territories. 76 Finally, pupillary involvement such as Adie pupil was also documented as a complication following COVID-19 infections. [77] [78] [79] 

As frontline clinicians directly involved in the care of patients, besides promptly recognizing ophthalmic manifestations of COVID-19 so that timely diagnosis and interventions can be arranged, ophthalmologists need to be aware of the potential side effects that may arise from treatments or preventive measures of COVID-19. 80, 81 Currently, therapeutic strategies for COVID-19 patients depend on the disease severity. General management of nonhospitalized patients with mild to moderate disease involves supportive care, isolation, and serial follow-up. In hospitalized patients, among patients with severe COVID-19 requiring supplemental oxygen for respiratory support, there is evidence supporting the use of the antiviral remdesivir, dexamethasone, and monoclonal antibodies. 82 Bamlanivimab, etesevimab, casirivimab, imdevimab, and sotrovimab are anti-SARS-CoV-2 monoclonal antibodies that have received emergency use authorizations from the Food and Drug Administration of the United States. 82 At the time of review, there have been no reports on adverse ocular effects of remdisivir and anti-SARS-CoV-2 monoclonal antibodies in the literature. Steroid is well known to produce ocular hypertension, which may necessitate glaucoma therapy to reduce the intraocular pressure (IOP) to eliminate the symptoms associated with the acute surge in IOP and prevent potential visual field loss. 83 The administration of steroids for treatment of COVID-19 was also reported to result in central serous chorioretinopathy. 84 In a series of 7 COVID-19 cases complicated by endogenous endophthalmitis, 6 cases were secondary to mucormycosis-associated sinusitis or systemic fungal infections, and all had received intravenous corticosteroid for COVID-19. 85 As prolonged use of systemic steroids creates an immunocompromised state and predisposes patients to such sight-threatening complications, ophthalmologists ought to have a high index of suspicion in their evaluation of these patients. The use of HCQ and CQ during the early COVID-19 period sparked heated debates within and beyond the ophthalmology community. There were initial concerns regarding its potential retinal toxicity and the development of Bull's eye maculopathy associated with its use. 13 Nevertheless, it is uncommon to develop retinopathy before 10 or more years of using such medications at the American Academy of Ophthalmology's recommended dosage of <5 mg/kg real weight. 86 As HCQ and CQ use in COVID-19 is only within a short period, it is extremely unlikely to produce such ocular complications. 13, 87 However, most of the evidence has shown no benefit of HCQ as compared to the standard of care across the different severities of COVID-19, and both drugs are no longer recommended by the latest evidence and treatment guidelines. 82, 88, 89 Complications from nonpharmacological interventions for COVID-19 patients have also been reported in the literature. Patients who developed severe pneumonia and respiratory failure related to COVID-19 often required intensive care and ventilatory support. The development of orbital emphysema extending from the chest to the face and periocular crepitus has been documented in COVID-19 patients placed on positive end-expiratory pressure ventilation. 90, 91 Furthermore, in patients who require advanced ventilatory support in the intensive care unit, exposure keratopathy was previously reported to develop in >50% of mechanically ventilated patients. 92 This can be attributed to the use of sedation and neuromuscular blocking agents which reduces the orbicularis muscle tone and prone positioning of the patients, both of which increase the risk of exposure keratopathy. 26, 93 The World Health Organization (WHO) has endorsed face masks to prevent transmission of COVID-19. Nevertheless, inappropriate use of masks can result in ocular complications. Nontraumatic orbital hemorrhage presented as sudden orbitalsubconjunctival-eyelid cutaneous hemorrhage-hematoma with conjunctival protrusion from the palpebral fissure has been reported in the improper fitting of face mask whereby excessive pressure was exerted on the nasal bridge and lower eyelid. 94 Alternatively, unsuitable fitting with face masks in which exhaled air flows across the ocular surface could exacerbate tear film evaporation and predispose patients to the development of dry eye. 95 At the beginning of the rapidly evolving pandemic, public fear and confusion regarding appropriate public health measures and behaviors to eliminate COVID-19 transmission have fuelled the dissemination of erroneous information and false beliefs. A patient developed bilateral complete vision loss within 24 hours following intentional ingestion of alcohol-based sanitizer solution. 96 Alcohol-based sanitizers usually contain ethanol, isopropyl alcohol, n-propyl alcohol, or their combinations as the major component. These agents had not been previously reported to result in vision loss. Retrospective investigation revealed that the patient in this case likely ingested a sanitizer that contained methyl alcohol (methanol), which is rapidly absorbed and metabolized into formaldehyde to produce ocular toxicity.

Currently, 6 commonly used vaccines in the Asia-Pacific region and the western world were granted the emergency use authorization (EUA) from WHO. The currently EUA qualified COVID-19 vaccines include mRNA vaccines (Pfizer-BioNTech, Moderna), adenovirus vector vaccines (AstraZeneca, Johnson & Johnson), and whole inactivated coronavirus vaccines (SinoPharm, Sinovac), and various systemic and ocular adverse effects have been reported in the literature. For instance, vaccine-induced immune thrombotic thrombocytopenia (VITT) and thrombosis resulting in potentially lethal thrombotic events have been reported after the administration of the AstraZeneca vaccine. [97] [98] [99] Therefore, ophthalmologists ought to be aware of potential ocular adverse effects that may arise subsequent to COVID-19 vaccination.

The Pfizer-BioNTech vaccine was reported to be associated with various ocular adverse effects. Reyes-Capo et al 100 reported a case of acute abducens nerve palsy following a febrile illness 2 days after vaccination in a patient without significant comorbidities. Various authors also reported cases of uveitis and Vogt-Koyanagi-Harada (VKH) disease following vaccination; most cases resolve or significantly improve following both steroidal and nonsteroidal immunosuppression. [101] [102] [103] A case of arteritic anterior ischemic optic neuropathy (AAION) manifesting as acute loss of vision following vaccination was also reported in the literature. 104 Finally, there were also recent reports of corneal graft rejection following vaccination in patients who received endothelial keratoplasty or penetrating keratoplasty. [105] [106] [107] As another mRNA vaccine, there is currently 1 report of bilateral acute zonal occult outer retinopathy (AZOOR) manifesting as progressive nasal field defect following Moderna vaccination. 104 Various adverse ocular effects have been reported after immunization by the AstraZeneca adenovirus vector vaccine. Acute macular neuroretinopathy, bilateral immune-mediated keratolysis, and VKH disease were all reported as potential adverse ocular events following vaccination. [108] [109] [110] Meanwhile, we did not identify reports of ocular adverse events following immunization by the Johnson & Johnson vaccine vaccine in the current literature.

A few adverse ocular effects were noted in the whole inactivated coronavirus vaccines. Following immunization, acute uveitis has been reported by the SinoPharm vaccine, which resolved with topical steroid treatment without recurrence. In a recent study, Pichi et al reported the presence of episcleritis, anterior scleritis, acute macular neuroretinopathy, paracentral acute middle maculopathy, and subretinal fluid from studying 7 patients who presented with ocular complaints following Sino-Pharm vaccination. 111 There was a report of bilateral transient visual field defect with spontaneous resolution in an ophthalmologist following Sinovac vaccination. 112 It should nonetheless be emphasized that with more than 1.5 billion doses of COVID-19 vaccinations administered worldwide, determining the causal relationship in every case of the potential adverse event becomes a daunting, if at all possible, challenge. With the enormous number of vaccinations administered, it may be natural for these events to be coincidental. 113 The astute clinician shall evaluate these events with scientific rigor based on all evidence, and bear in mind the vast number of lives and benefits vaccination and herd immunity would bring to the society overall.

The SARS-CoV-2 emerged in late 2019 when the entire world knew little of it. As the pandemic continues to evolve with the advent of new viral variants, the medical community also witnesses a boom in knowledge and information covering all facets of the pathogen. This review summarized the ophthalmic manifestations and adverse ocular effects resulting from therapeutic and preventive measures of COVID-19, which can guide ophthalmologists in their clinical encounters of COVID-19 patients in the battle ahead.

Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant

Impact of COVID-19 on ophthalmology and future practice of medicine

Evolving practice patterns in Singapore's public sector ophthalmology centers during the COVID-19 pandemic

ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection

Expression of the SARS-CoV-2 receptor ACE2 in human retina and diabetes-implications for retinopathy

Role of the eye in transmitting human coronavirus: what we know and what we do not know. Front Public Health

Conjunctivitis can be the only presenting sign and symptom of COVID-19

Ocular manifestations and clinical characteristics of 535 cases of COVID-19 in Wuhan, China: a crosssectional study

Assessing viral shedding and infectivity of tears

The evidence of SARS-CoV-2 infection on ocular surface

Ocular Symptoms among nonhospitalized patients who underwent COVID-19 testing

Risk of SARS-CoV-2 transmission via corneal transplant from donors with COVID-19

Chloroquine and hydroxychloroquine retinal toxicity consideration in the treatment of COVID-19

Endogenous endophthalmitis in the setting of COVID-19 infection: a case series

Structure of the SARS-CoV-2 spike receptorbinding domain bound to the ACE2 receptor

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19

Novel coronavirus disease 2019 (COVID-19): the importance of recognising possible early ocular manifestation and using protective eyewear

COVID-19 and conjunctivitis: a meta-analysis

Clinical characteristics of coronavirus disease 2019 in China

COVID-19 and acute conjunctivitis: controversial data from a tertiary refferral Italian center

Letter to the editor: are severe COVID-19 patients more susceptible to conjunctivitis

Late manifestation of follicular conjunctivitis in ventilated patient following COVID-19 positive severe pneumonia

Haemorrhagic conjunctivitis with pseudomembranous related to SARS-CoV-2

Conjunctivitis and COVID-19: a meta-analysis

Conjunctival findings in patients with coronavirus disease 2019

Ocular findings and proportion with conjunctival SARS-COV-2 in COVID-19 patients

Evaluation of SARS-CoV-2 in tears of patients with moderate to severe COVID-19

COVID-19: special precautions in ophthalmic practice and FAQs on personal protection and mask selection

Relapsing viral keratoconjunctivitis in COVID-19: a case report

Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19)

Recurrent keratoconjunctivitis as the sole manifestation of COVID-19 infection: A case report

Episcleritis as an ocular manifestation in a patient with COVID-19

Episcleritis as a possible presenting sign of the novel coronavirus disease: A case report

Orbital cellulitis, sinusitis and intracranial abnormalities in two adolescents with COVID-19

Rhino-orbital mucormycosis associated with COVID-19

Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report

COVID-19 coinfection with mucormycosis in a diabetic patient

Post COVID-19 Infection presenting as rhino-orbital mycosis

Post-COVID-19 rhino-orbito-cerebral mucormycosis: a new addition to challenges in pandemic control

Mucormycosis in a patient with COVID-19 with uncontrolled diabetes

Rhino-orbital mucormycosis in a COVID-19 patient co-infected with klebsiella pneumoniae

Mucormycosis after COVID-19 in a patient with diabetes

Sino-orbital mucormycosis in a COVID-19 patient: A case report

Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19

Rhino-orbital mucormycosis following COVID-19 in previously non-diabetic, immunocompetent patients

Panuveitis and optic neuritis as a possible initial presentation of the novel coronavirus disease 2019 (COVID-19)

Retinal findings in patients with COVID-19

Retinal findings in hospitalised patients with severe COVID-19

COVID-19-associated retinopathy: a case report

Atypical bilateral acute retinal necrosis in a coronavirus disease 2019 positive immunosuppressed patient

Disease of the year: COVID-19 and its neuroophthalmic complications

COVID-19-associated Miller Fisher syndrome: MRI findings

Miller Fisher syndrome and polyneuritis cranialis in COVID-19

COVID-19 presenting with ophthalmoparesis from cranial nerve palsy

Acute abducens nerve palsy in a patient with the novel coronavirus disease (COVID-19)

COVID-19-associated ophthalmoparesis and hypothalamic involvement

Third cranial nerve palsy presenting with unilateral diplopia and strabismus in a 24-year-old woman with COVID-19

Isolated cranial nerve 6 palsy in 6 patients with COVID-19 infection

Concurrent tonic pupil and trochlear nerve palsy in COVID-19

Postinfectious onset of myasthenia gravis in a COVID-19 patient

Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis and myelitis in COVID-19

Eye diseases direct interest to complement pathway and macrophages as regulators of inflammation in COVID-19

Papillophlebitis in a COVID-19 patient: inflammation and hypercoagulable state

Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban

Retinal vein occlusion in COVID-19: a novel entity

Bilateral central retinal vein occlusion in a 40-year-old man with severe coronavirus disease 2019 (COVID-19) pneumonia

Central retinal vein occlusion with COVID-19 infection as the presumptive etiology

Impending central retinal vein occlusion in a patient

Acute vision loss in a patient with COVID-19

Unique case of central retinal artery occlusion secondary to COVID-19 disease

Case report: central retinal artery occlusion in a COVID-19 patient

Severe bilateral vision loss in 2 patients with coronavirus disease 2019

Ophthalmic and neuro-ophthalmic manifestations of coronavirus disease 2019 (COVID-19)

Adie-Holmes syndrome associated with COVID-19 infection: a case report

Tonic pupil following COVID 19

COVID-19: ocular manifestations and the APAO prevention guidelines for ophthalmic practices

Precautionary measures needed for ophthalmologists during pandemic of the coronavirus disease 2019 (COVID-19)

Case report: steroid-induced ocular hypertension in a 6-year-old boy

Old wine in a new bottle" -post COVID-19 infection, central serous chorioretinopathy and the steroids

Unveiling endophthalmitis post COVID-19 -a case series

Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy

COVID-19 and chloroquine/hydroxychloroquine: is there ophthalmological concern?

A cluster-randomized trial of hydroxychloroquine for prevention of COVID-19

Observational study of hydroxychloroquine in hospitalized patients with COVID-19

Complications of orbital emphysema in a COVID-19 patient

Unilateral orbital emphysema in a COVID-19 patient

Exposure keratopathy in sedated and ventilated patients

Eye care in the intensive care unit during the COVID-19 pandemic and beyond

Orbitalconjunctival-eyelid hemorrhage-hematoma due to inappropriate use of FFP2/NK95 facial mask in COVID-19

Mask-associated dry eye disease and dry eye due to prolonged screen time: are we heading towards a new dry eye epidemic during the COVID-19 era?

COVID casualty: bilateral blindness due to ingestion of spurious sanitizer

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination

SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia

Acute abducens nerve palsy following COVID-19 vaccination

Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination

Uveitis following the BNT162b2 mRNA vaccination against SARS-CoV-2 infection: a possible association

Panuveitis following vaccination for COVID-19

COVID-19 recombinant mrna vaccines and serious ocular inflammatory side effects: real or coincidence?

Keratoplasty rejection after the BNT162b2 messenger RNA vaccine

Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine

Corneal graft rejection following COVID-19 vaccine

Acute macular neuroretinopathy following COVID-19 vaccination

Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2 recombinant viral vector vaccine

Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine

Association of ocular adverse events with inactivated COVID-19 vaccination in patients in Abu Dhabi

Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report

COVID-19 vaccinations, and subsequent abnormalities in the retina: causation or